 
        
        
        Search
 
    
     
                 
                 
                 
               
               
              Dasatinib anhydrous for sale is used in chronic myeloid leukemia that is resistant or intolerable to treatment regimens including imatinib mesylate.
Dasatinib anhydrous is a protein kinase inhibitor that inhibits BCR-ABL kinase and SRC family kinases and many other selective oncogenic kinases, including c-KIT, ephrin (EPH) receptor kinase, and PDGFβ receptor, dasatinib anhydrous primarily treats adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) chronic, accelerated, and blast phase (acute granulosis and blast leaching) resistant to imatinib mesylate, or intolerance.
| Items | Specifications | Results | 
| Appearance | White powder | Conforms | 
| Assay | ≥99.0% | 99.63% | 
| Product parameters | |
| Cas number: | 302962-49-8 | 
| Appearance: | White powder | 
| Purity: | 99%min | 
| Package details: | 100g/bottle; 1kg/foil bag | 
| Brand: | Fortunachem | 

Suitable for treatment of chronic myeloid leukemia.

 
      Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!
 
        
      Quick Links
Add:
E-mail:
 English
English                   Español
Español                   français
français                   العربية
العربية                   
                                                                                                                                             
                                                                                                                                                                                       
                                                                                                                                                                                       
                                                                                                                                                                                       
                       
                       
                      